Pub Date : 2023-05-01Epub Date: 2023-12-01DOI: 10.4103/ijt.ijt_39_22
Ralph Michel Trüeb, Ngoc-Nhi Catharina Luu, Hudson Dutra Rezende
Folliculitis decalvans (FD) represents a chronic and recurrent pustulofollicular scalp inflammation resulting in scarring alopecia. The presence of a bacterial bioflilm at the interface of the hair shaft may provide an explanation for the chronicity and high relapse rate of FD, even after prolonged systemic antibiotic treatments. We originally read with enthusiasm Melián-Olivera et al.'s retrospective study of patients with FD treated with topical dapsone published in the Journal of the American Academy of Dermatology. However, we experienced an unsuccessful trial of 5% dapsone gel in a patient with FD resulting in worsening of the disease with a pustular flareup and questioned why positive study reports with novel therapeutic options in dermatology often fail in practice. The authors admitted the limitations of their study: small sample size, retrospective, uncontrolled nature of the study, and concomitant use of other treatments. Clinical research ultimately aims at improving the patient outcome. For this purpose, trials must evaluate the outcomes that genuinely reflect the clinical utility of drugs. Therefore, we postulate stricter criteria for treatment trials and statistics in dermatology before publication in peer-reviewed scientific journals to avoid frustrations of physicians and patients alike.
脱发性毛囊炎(FD)是一种慢性、复发性脓疱性头皮炎症,可导致瘢痕性脱发。毛囊炎是一种慢性、复发性脓疱性毛囊头皮炎症,可导致瘢痕性脱发。毛干界面存在细菌生物膜,这可能是毛囊炎慢性化和高复发率的原因之一,即使经过长期的全身抗生素治疗也是如此。我们最初以极大的热情阅读了 Melián-Olivera 等人在《美国皮肤病学会杂志》(Journal of the American Academy of Dermatology)上发表的关于 FD 患者接受外用达泊松治疗的回顾性研究。然而,我们曾在一位FD患者身上试用过5%的达松凝胶,但并不成功,结果导致病情恶化,脓疱复发,我们不禁要问,为什么皮肤科新疗法的积极研究报告往往在实践中失败。作者承认他们的研究存在局限性:样本量小、研究具有回顾性和不可控性,以及同时使用了其他治疗方法。临床研究的最终目的是改善患者的治疗效果。为此,试验必须对真正反映药物临床效用的结果进行评估。因此,我们建议在同行评审的科学杂志上发表皮肤病学治疗试验和统计数据之前,应制定更严格的标准,以避免医生和患者的失望。
{"title":"Comment on Topical Dapsone for Folliculitis Decalvans.","authors":"Ralph Michel Trüeb, Ngoc-Nhi Catharina Luu, Hudson Dutra Rezende","doi":"10.4103/ijt.ijt_39_22","DOIUrl":"10.4103/ijt.ijt_39_22","url":null,"abstract":"<p><p>Folliculitis decalvans (FD) represents a chronic and recurrent pustulofollicular scalp inflammation resulting in scarring alopecia. The presence of a bacterial bioflilm at the interface of the hair shaft may provide an explanation for the chronicity and high relapse rate of FD, even after prolonged systemic antibiotic treatments. We originally read with enthusiasm Melián-Olivera <i>et al</i>.'s retrospective study of patients with FD treated with topical dapsone published in the <i>Journal of the American Academy of Dermatology</i>. However, we experienced an unsuccessful trial of 5% dapsone gel in a patient with FD resulting in worsening of the disease with a pustular flareup and questioned why positive study reports with novel therapeutic options in dermatology often fail in practice. The authors admitted the limitations of their study: small sample size, retrospective, uncontrolled nature of the study, and concomitant use of other treatments. Clinical research ultimately aims at improving the patient outcome. For this purpose, trials must evaluate the outcomes that genuinely reflect the clinical utility of drugs. Therefore, we postulate stricter criteria for treatment trials and statistics in dermatology before publication in peer-reviewed scientific journals to avoid frustrations of physicians and patients alike.</p>","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"88-90"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01Epub Date: 2023-12-01DOI: 10.4103/ijt.ijt_90_23
Nitika Wagh
{"title":"Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata.","authors":"Nitika Wagh","doi":"10.4103/ijt.ijt_90_23","DOIUrl":"10.4103/ijt.ijt_90_23","url":null,"abstract":"","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"113-114"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01Epub Date: 2023-12-01DOI: 10.4103/ijt.ijt_91_23
Amit Bharat Shah
{"title":"A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata.","authors":"Amit Bharat Shah","doi":"10.4103/ijt.ijt_91_23","DOIUrl":"10.4103/ijt.ijt_91_23","url":null,"abstract":"","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"115-116"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01Epub Date: 2023-12-01DOI: 10.4103/ijt.ijt_55_22
Ralph Michel Trüeb
Background: Androgenetic alopecia leads to progressive hair loss in susceptible individuals if left untreated. Topical minoxidil represents an evidence-based treatment for female androgenetic alopecia, though with variable success.
Aims and objectives: Treatment of minoxidil non-responders remains challenging, as does treatment of patients with propylene glycol sensitivity or irritable scalp syndrome.
Materials and methods: Single-center, retrospective cohort of 50 female patients with androgenetic alopecia failing to respond to a minimum of 6 months of standard 5% topical minoxidil solution either once daily or b.i.d. depending on the severity of the alopecia. Patients were switched to propylene glycol-free, North American Witch Hazel (Hamamelis virginiana)-based solution of 5% minoxidil sulfate (5% minoxidil sensitive solution). Efficacy and safety of treatment were evaluated, including stereotactic global photography and epiluminiscence microscopy with digital imaging taken at baseline, at 3, and at 6 months of treatment.
Results: 70% of patients showed observable clinical improvement with combined global photographic and epiluminiscence microscopic assessment with digital imaging, and 22% epiluminiscence microscopic-only improvement as evidence of treatment efficacy. The treatment was well tolerated, particularly in patients with propylene glycol sensitivity and patients with irritable scalp syndrome.
Conclusions: These results suggest that propylene glycol-free, North American witch hazel (Hamamelis virginiana)-based solution of 5% minoxidil is effective and safe for treatment of female androgenetic alopecia, specifically in minoxidil non-responders and patients with propylene glycol sensitivity or irritable scalp syndrome.
{"title":"Efficacy, Tolerability, and Superiority of Propylene Glycol-Free, North American Witch-Hazel (<i>Hamamelis virginiana</i>)-Based Solution of 5% Minoxidil Sulfate for the Treatment of Female Androgenetic Alopecia.","authors":"Ralph Michel Trüeb","doi":"10.4103/ijt.ijt_55_22","DOIUrl":"10.4103/ijt.ijt_55_22","url":null,"abstract":"<p><strong>Background: </strong>Androgenetic alopecia leads to progressive hair loss in susceptible individuals if left untreated. Topical minoxidil represents an evidence-based treatment for female androgenetic alopecia, though with variable success.</p><p><strong>Aims and objectives: </strong>Treatment of minoxidil non-responders remains challenging, as does treatment of patients with propylene glycol sensitivity or irritable scalp syndrome.</p><p><strong>Materials and methods: </strong>Single-center, retrospective cohort of 50 female patients with androgenetic alopecia failing to respond to a minimum of 6 months of standard 5% topical minoxidil solution either once daily or b.i.d. depending on the severity of the alopecia. Patients were switched to propylene glycol-free, North American Witch Hazel (Hamamelis virginiana)-based solution of 5% minoxidil sulfate (5% minoxidil sensitive solution). Efficacy and safety of treatment were evaluated, including stereotactic global photography and epiluminiscence microscopy with digital imaging taken at baseline, at 3, and at 6 months of treatment.</p><p><strong>Results: </strong>70% of patients showed observable clinical improvement with combined global photographic and epiluminiscence microscopic assessment with digital imaging, and 22% epiluminiscence microscopic-only improvement as evidence of treatment efficacy. The treatment was well tolerated, particularly in patients with propylene glycol sensitivity and patients with irritable scalp syndrome.</p><p><strong>Conclusions: </strong>These results suggest that propylene glycol-free, North American witch hazel (<i>Hamamelis virginiana</i>)-based solution of 5% minoxidil is effective and safe for treatment of female androgenetic alopecia, specifically in minoxidil non-responders and patients with propylene glycol sensitivity or irritable scalp syndrome.</p>","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"108-112"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01Epub Date: 2023-12-01DOI: 10.4103/ijt.ijt_70_23
Kiran Godse, Abhishek De, Maya Vedamurthy, D S Krupa Shankar, Bela Shah, Mukesh Girdhar, Ramesh Bhat, Anil Ganjoo, Sushil Tahiliani, Anant Patil
Alopecia is a highly prevalent condition worldwide including in India. There are different types of alopecia with differing etiology, presentation, and hence treatment. Androgenetic alopecia represents the most common form of hair loss affecting male as well as female population termed as male and female pattern hair loss, respectively. Several treatment options are available for the treatment of alopecia with often unsatisfactory results resulting in psychological distress among such patients. Topical minoxidil is known to be effective in the treatment of alopecia. However, oral minoxidil is not currently approved for the treatment of alopecia. This expert consensus is prepared to provide guidance to the clinicians regarding the use of oral minoxidil in the treatment of alopecia. Extensive literature review was performed to prepare the draft consensus which was then revised based on the suggestions and comments from the experts. The final draft was circulated to the experts for review and approval. This consensus document provides overview of evidence related to oral minoxidil and consensus from the experts for its use in the treatment of minoxidil.
{"title":"Low-dose Oral Minoxidil in the Treatment of Alopecia: Evidence and Experience-based Consensus Statement of Indian Experts.","authors":"Kiran Godse, Abhishek De, Maya Vedamurthy, D S Krupa Shankar, Bela Shah, Mukesh Girdhar, Ramesh Bhat, Anil Ganjoo, Sushil Tahiliani, Anant Patil","doi":"10.4103/ijt.ijt_70_23","DOIUrl":"10.4103/ijt.ijt_70_23","url":null,"abstract":"<p><p>Alopecia is a highly prevalent condition worldwide including in India. There are different types of alopecia with differing etiology, presentation, and hence treatment. Androgenetic alopecia represents the most common form of hair loss affecting male as well as female population termed as male and female pattern hair loss, respectively. Several treatment options are available for the treatment of alopecia with often unsatisfactory results resulting in psychological distress among such patients. Topical minoxidil is known to be effective in the treatment of alopecia. However, oral minoxidil is not currently approved for the treatment of alopecia. This expert consensus is prepared to provide guidance to the clinicians regarding the use of oral minoxidil in the treatment of alopecia. Extensive literature review was performed to prepare the draft consensus which was then revised based on the suggestions and comments from the experts. The final draft was circulated to the experts for review and approval. This consensus document provides overview of evidence related to oral minoxidil and consensus from the experts for its use in the treatment of minoxidil.</p>","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"91-97"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01Epub Date: 2023-12-01DOI: 10.4103/ijt.ijt_31_21
Pooja Agarwal, Krishna M Gajjar, Ashish Jagati, Snehal V Chaudhari, Santoshdev P Rathod
Introduction: Androgenetic alopecia (AGA) is defined as progressive, patterned hair loss that occurs as a result of androgen-mediated conversion of terminal hairs to vellus hairs. By the age of 60 years, 45% of men and 35% of women develop AGA. The Hamilton-Norwood scale is used to assess the extent and severity of AGA and classify the stages of male pattern hair loss in men, whereas the Ludwig scale is preferred for women. Currently, U.S. Food and Drug Administration-approved treatments for AGA include oral finasteride and topical minoxidil. Due to the limited number of effective therapies for AGA, platelet-rich plasma (PRP) has become an effective alternative treatment. A number of studies on PRP have shown promising results, leading to increased hair density and thickness with minimal or no side effects.
Aims: We aim to study the safety, efficacy, and side effects of PRP therapy in patients of AGA and to study demographic data in the form of age, sex, age of onset of hair loss, and grade of AGA in patients.
Materials and methods: Fifty patients, 38 males and 12 females, with AGA were enrolled in the study. PRP was prepared using a double-spin method. Upon activation, PRP was injected in the involved areas of scalp once every 2 weeks for 6 months. Follow-up photos were taken every 3 months.
Results: At 6 months, majority of the patients (45%) were unsatisfied and showed no change in hair growth after PRP therapy and few patients were lost in follow-up. Adverse effects were minimal and no long-term serious adverse effects were noted.
Conclusion: We conclude from the results in our study that PRP therapy is not significantly effective in treatment of AGA. There is a need to develop standard protocols with regard to total length of PRP therapy and spacing between the two sessions of PRP for AGA.
导言:雄激素性脱发(AGA)是指由雄激素介导的末端毛发向绒毛转化而导致的进行性、模式化脱发。到 60 岁时,45% 的男性和 35% 的女性会患上 AGA。汉密尔顿-诺伍德量表(Hamilton-Norwood scale)用于评估男性 AGA 的范围和严重程度,并对男性脱发进行分期,而路德维希量表(Ludwig scale)则适用于女性。目前,美国食品和药物管理局批准的 AGA 治疗方法包括口服非那雄胺和外用米诺地尔。由于治疗 AGA 的有效疗法数量有限,富血小板血浆(PRP)已成为一种有效的替代疗法。目的:我们旨在研究 PRP 治疗 AGA 患者的安全性、有效性和副作用,并研究患者的年龄、性别、脱发发病年龄和 AGA 等级等人口统计学数据:研究共招募了 50 名 AGA 患者,其中男性 38 名,女性 12 名。采用双旋法制备 PRP。激活后,每两周在头皮相关区域注射一次 PRP,持续 6 个月。每 3 个月拍摄一次随访照片:结果:6 个月后,大多数患者(45%)对 PRP 治疗不满意,头发生长没有变化,少数患者失去了随访机会。不良反应极小,未发现长期严重不良反应:我们从研究结果中得出结论,PRP疗法对AGA的治疗效果并不明显。有必要就 PRP 治疗的总时长和两次 PRP 治疗之间的间隔制定标准方案。
{"title":"Platelet-Rich Plasma in Androgenetic Alopecia: Is It Really Worth the Hype?","authors":"Pooja Agarwal, Krishna M Gajjar, Ashish Jagati, Snehal V Chaudhari, Santoshdev P Rathod","doi":"10.4103/ijt.ijt_31_21","DOIUrl":"10.4103/ijt.ijt_31_21","url":null,"abstract":"<p><strong>Introduction: </strong>Androgenetic alopecia (AGA) is defined as progressive, patterned hair loss that occurs as a result of androgen-mediated conversion of terminal hairs to vellus hairs. By the age of 60 years, 45% of men and 35% of women develop AGA. The Hamilton-Norwood scale is used to assess the extent and severity of AGA and classify the stages of male pattern hair loss in men, whereas the Ludwig scale is preferred for women. Currently, U.S. Food and Drug Administration-approved treatments for AGA include oral finasteride and topical minoxidil. Due to the limited number of effective therapies for AGA, platelet-rich plasma (PRP) has become an effective alternative treatment. A number of studies on PRP have shown promising results, leading to increased hair density and thickness with minimal or no side effects.</p><p><strong>Aims: </strong>We aim to study the safety, efficacy, and side effects of PRP therapy in patients of AGA and to study demographic data in the form of age, sex, age of onset of hair loss, and grade of AGA in patients.</p><p><strong>Materials and methods: </strong>Fifty patients, 38 males and 12 females, with AGA were enrolled in the study. PRP was prepared using a double-spin method. Upon activation, PRP was injected in the involved areas of scalp once every 2 weeks for 6 months. Follow-up photos were taken every 3 months.</p><p><strong>Results: </strong>At 6 months, majority of the patients (45%) were unsatisfied and showed no change in hair growth after PRP therapy and few patients were lost in follow-up. Adverse effects were minimal and no long-term serious adverse effects were noted.</p><p><strong>Conclusion: </strong>We conclude from the results in our study that PRP therapy is not significantly effective in treatment of AGA. There is a need to develop standard protocols with regard to total length of PRP therapy and spacing between the two sessions of PRP for AGA.</p>","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"98-104"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-01Epub Date: 2023-12-01DOI: 10.4103/ijt.ijt_15_23
Ralph Michel Trüeb, Aida Gadzhigoroeva, Daisy Kopera, Ngoc-Nhi Catharina Luu, Angelina Dmitriev
Karl Marx and Friedrich Engels exposed a pattern of societal conduct they chose to name capitalistic bourgeoisie. The bourgeoisie created a common language of communication through collaboration, gathered in circles such as free academies, scientific academies, literary circles, and the media, that provided forums for the emerging bourgeoisie to conceive of new social orders. One aspect of bourgeoisie culture is conspicuous consumption, central to which, is a culture of prestige through material consumption. Capitalism is an economic system based on private ownership and the operation for profit. Characteristic features of capitalism include competitive market, commercialism, property rights recognition, capital accumulation, material consumption, culture of prestige, sycophancy, and coterie. Critiques of capitalism allege that it is exploitative, alienating, unstable, unsustainable, and inefficient. In turn, critical theory inspired philosophers such as Michel Foucault to conceptualize how we form identities through social interaction. When the patient's body entered the field of medicine, it also entered the field of power where the patient can be manipulated by professional authority. Without forcibly being a proponent of political theory, as an academic, one is inevitably confronted with Marxism in terms of philosophy. As a discipline at the interface of medicine, lifestyle, and cosmetics, trichology is particularly susceptible to the primary aims of profit, consumption, and prestige that characterize the capitalistic bourgeoisie. The trichological sciences, particularly trichoscopy, have discovered a profitable market for itself. The practice of trichology is not immune to malpractice. It has created an industry that dwells on the autistic thinking of patients and doctors, and because it is prosperous, makes propaganda among lay people and doctors that necessarily leads to abuses.
{"title":"The Problem with Capitalism in the Trichological Sciences.","authors":"Ralph Michel Trüeb, Aida Gadzhigoroeva, Daisy Kopera, Ngoc-Nhi Catharina Luu, Angelina Dmitriev","doi":"10.4103/ijt.ijt_15_23","DOIUrl":"10.4103/ijt.ijt_15_23","url":null,"abstract":"<p><p>Karl Marx and Friedrich Engels exposed a pattern of societal conduct they chose to name capitalistic bourgeoisie. The bourgeoisie created a common language of communication through collaboration, gathered in circles such as free academies, scientific academies, literary circles, and the media, that provided forums for the emerging bourgeoisie to conceive of new social orders. One aspect of bourgeoisie culture is conspicuous consumption, central to which, is a culture of prestige through material consumption. Capitalism is an economic system based on private ownership and the operation for profit. Characteristic features of capitalism include competitive market, commercialism, property rights recognition, capital accumulation, material consumption, culture of prestige, sycophancy, and coterie. Critiques of capitalism allege that it is exploitative, alienating, unstable, unsustainable, and inefficient. In turn, critical theory inspired philosophers such as Michel Foucault to conceptualize how we form identities through social interaction. When the patient's body entered the field of medicine, it also entered the field of power where the patient can be manipulated by professional authority. Without forcibly being a proponent of political theory, as an academic, one is inevitably confronted with Marxism in terms of philosophy. As a discipline at the interface of medicine, lifestyle, and cosmetics, trichology is particularly susceptible to the primary aims of profit, consumption, and prestige that characterize the capitalistic bourgeoisie. The trichological sciences, particularly trichoscopy, have discovered a profitable market for itself. The practice of trichology is not immune to malpractice. It has created an industry that dwells on the autistic thinking of patients and doctors, and because it is prosperous, makes propaganda among lay people and doctors that necessarily leads to abuses.</p>","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 3","pages":"79-84"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01Epub Date: 2023-07-28DOI: 10.4103/ijt.ijt_41_22
Jisha Pillai, Nilesh Goyal
Segmental vitiligo (SV) has been identified as a type of vitiligo starting early on in life with a rapidly progressive depigmentation in the affected area. Surgical modalities have shown better outcomes in SV compared with medical therapies. Perifollicular repigmentation being the mode of pigment spread after surgical treatments, follicular unit extraction graft surgery has shown complete repigmentation with minimal postoperative scarring. We present a case of SV where hair transplant surgery was done using scalp hair and pubic hair grafts at different times achieving complete repigmentation with photochemotherapy.
{"title":"Repigmentation of Segmental Vitiligo with Scalp and Pubic Follicular Unit Extraction Graft Transplantation.","authors":"Jisha Pillai, Nilesh Goyal","doi":"10.4103/ijt.ijt_41_22","DOIUrl":"10.4103/ijt.ijt_41_22","url":null,"abstract":"<p><p>Segmental vitiligo (SV) has been identified as a type of vitiligo starting early on in life with a rapidly progressive depigmentation in the affected area. Surgical modalities have shown better outcomes in SV compared with medical therapies. Perifollicular repigmentation being the mode of pigment spread after surgical treatments, follicular unit extraction graft surgery has shown complete repigmentation with minimal postoperative scarring. We present a case of SV where hair transplant surgery was done using scalp hair and pubic hair grafts at different times achieving complete repigmentation with photochemotherapy.</p>","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 2","pages":"70-73"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10239702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01Epub Date: 2023-07-28DOI: 10.4103/ijt.ijt_72_22
Apoorva V Bharadwaj, Vibhu Mendiratta, Harmeet Singh Rehan, Smita Tripathi
Background: Androgenetic alopecia (AGA) is the most common cause of hair loss in males which remains a therapeutic challenge.
Objectives: To compare the efficacy of topical 5% minoxidil and 0.25% finasteride combination (MNF) over 5% minoxidil (MNX) or 0.25% finasteride (FNS) alone by assessing hair count, physician assessment score (PAS), and patient satisfaction score (PSS).
Materials and methods: Pilot randomized open-label study where 60 male patients with AGA ≥ III grade were randomized into three treatment groups and evaluated over 24 weeks. Improvement in hair count was assessed manually using dermoscopy. Global photographs were used to assess PAS. Side effects were evaluated using relevant laboratory investigations.
Results: At the 12th and 24th week, all three groups showed significant improvement in total hair density as compared to baseline (P < 0.001). None of the groups was superior to the other (P > 0.05) at the 12th week but at 24th week, MNF was comparatively superior (P < 0.02). At the 12th week and 24th week, all three groups showed significant improvement in terminal hair density as compared to baseline (P < 0.001). In the 12th week, MNF was comparatively superior (P = 0.028) and at the 24th week, MNF was comparatively superior (P < 0.02). PAS and PSS were significantly better with MNF and MNX compared to FNS (P < 0.004). Side effects such as scaling and itching were reported with MNF and MNX.
Conclusion: Topical minoxidil 5% and finasteride 0.25% had an overall better efficacy compared to monotherapy without significant side effects.
{"title":"Comparative Efficacy of Topical Finasteride (0.25%) in Combination with Minoxidil (5%) Against 5% Minoxidil or 0.25% Finasteride Alone in Male Androgenetic Alopecia: A Pilot, Randomized Open-Label Study.","authors":"Apoorva V Bharadwaj, Vibhu Mendiratta, Harmeet Singh Rehan, Smita Tripathi","doi":"10.4103/ijt.ijt_72_22","DOIUrl":"10.4103/ijt.ijt_72_22","url":null,"abstract":"<p><strong>Background: </strong>Androgenetic alopecia (AGA) is the most common cause of hair loss in males which remains a therapeutic challenge.</p><p><strong>Objectives: </strong>To compare the efficacy of topical 5% minoxidil and 0.25% finasteride combination (MNF) over 5% minoxidil (MNX) or 0.25% finasteride (FNS) alone by assessing hair count, physician assessment score (PAS), and patient satisfaction score (PSS).</p><p><strong>Materials and methods: </strong>Pilot randomized open-label study where 60 male patients with AGA ≥ III grade were randomized into three treatment groups and evaluated over 24 weeks. Improvement in hair count was assessed manually using dermoscopy. Global photographs were used to assess PAS. Side effects were evaluated using relevant laboratory investigations.</p><p><strong>Results: </strong>At the 12<sup>th</sup> and 24<sup>th</sup> week, all three groups showed significant improvement in total hair density as compared to baseline (<i>P</i> < 0.001). None of the groups was superior to the other (<i>P</i> > 0.05) at the 12<sup>th</sup> week but at 24<sup>th</sup> week, MNF was comparatively superior (<i>P</i> < 0.02). At the 12<sup>th</sup> week and 24<sup>th</sup> week, all three groups showed significant improvement in terminal hair density as compared to baseline (<i>P</i> < 0.001). In the 12<sup>th</sup> week, MNF was comparatively superior (<i>P</i> = 0.028) and at the 24<sup>th</sup> week, MNF was comparatively superior (<i>P</i> < 0.02). PAS and PSS were significantly better with MNF and MNX compared to FNS (<i>P</i> < 0.004). Side effects such as scaling and itching were reported with MNF and MNX.</p><p><strong>Conclusion: </strong>Topical minoxidil 5% and finasteride 0.25% had an overall better efficacy compared to monotherapy without significant side effects.</p>","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 2","pages":"56-62"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10244519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01Epub Date: 2023-07-28DOI: 10.4103/ijt.ijt_70_22
Michaela Rose Rand, Katerina Yale, Brian Satoshi Kato, Dong Joo Kim, Suzanne Birmingham, Natasha Atanaskova Mesinkovska
Complete scalp hair loss can be a source of distress for affected children and their families. In addition to infectious and trauma-related causes of hair loss, infants and children may present with total scalp alopecia arising from a range of genetic predispositions. Our objective with this review was to identify the common genetic conditions in children with complete scalp alopecia. The PubMed Database was reviewed for all articles from 1962 to 2019 containing the search terms related to genetic alopecia. The conditions with at least five reported cases in the literature were considered for the inclusion. All clinical trials, retrospective studies, and cases on human subjects and written in English were included. Six genetic conditions related to complete scalp alopecia were included in this review. The most common genetic conditions associated with total scalp hair loss include: alopecia totalis/Alopecia universalis (AU), atrichia with papular lesions, AU congenita, hereditary Vitamin D-resistant rickets type IIA, alopecia with mental retardation, and pure hair and nail ectodermal dysplasia. In children presenting with total scalp hair loss, a myriad of genetic and environmental factors may be the underlying cause. Increased awareness of potential genetic conditions associated with total scalp hair loss may assist in diagnosis, with improved the prognosis for the children.
{"title":"Commonly Associated Disorders with Complete Scalp Alopecia in Early Childhood: A Review.","authors":"Michaela Rose Rand, Katerina Yale, Brian Satoshi Kato, Dong Joo Kim, Suzanne Birmingham, Natasha Atanaskova Mesinkovska","doi":"10.4103/ijt.ijt_70_22","DOIUrl":"10.4103/ijt.ijt_70_22","url":null,"abstract":"<p><p>Complete scalp hair loss can be a source of distress for affected children and their families. In addition to infectious and trauma-related causes of hair loss, infants and children may present with total scalp alopecia arising from a range of genetic predispositions. Our objective with this review was to identify the common genetic conditions in children with complete scalp alopecia. The PubMed Database was reviewed for all articles from 1962 to 2019 containing the search terms related to genetic alopecia. The conditions with at least five reported cases in the literature were considered for the inclusion. All clinical trials, retrospective studies, and cases on human subjects and written in English were included. Six genetic conditions related to complete scalp alopecia were included in this review. The most common genetic conditions associated with total scalp hair loss include: alopecia totalis/Alopecia universalis (AU), atrichia with papular lesions, AU congenita, hereditary Vitamin D-resistant rickets type IIA, alopecia with mental retardation, and pure hair and nail ectodermal dysplasia. In children presenting with total scalp hair loss, a myriad of genetic and environmental factors may be the underlying cause. Increased awareness of potential genetic conditions associated with total scalp hair loss may assist in diagnosis, with improved the prognosis for the children.</p>","PeriodicalId":14417,"journal":{"name":"International Journal of Trichology","volume":"15 2","pages":"43-49"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10232604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}